Codexis (CDXS) Stock Price, News & Analysis

Company Overview

Codexis, Inc., headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production. The company operates advanced research and development laboratories alongside cGMP manufacturing facilities, allowing for seamless scale-up of enzyme processes. Its multidisciplinary team of molecular biologists, biochemists and process engineers collaborates closely with clients to integrate tailored enzyme solutions into existing production workflows.

Codexis’s biocatalysts have been applied to the synthesis of active pharmaceutical ingredients, delivering streamlined routes and cost reductions in drug manufacturing. Beyond pharmaceuticals, the company addresses challenges in the food and beverage sector—such as flavor enhancement and ingredient processing—and in the fine chemicals and agricultural markets. Codexis’s commitment to sustainable biocatalysis supports industry efforts toward greener chemistry and resource conservation.

Serving a global customer base, Codexis engages in partnerships and licensing arrangements with leading industrial and pharmaceutical organizations. Its commercial model typically combines research funding, milestone payments and royalty streams, positioning the company for diversified revenue growth across multiple projects. With an emphasis on innovation and environmental stewardship, Codexis continues to drive advancements in the burgeoning field of enzyme-based manufacturing.

Key Stats

• Today's Range: $2.41 to $2.50
• 50-Day Range: $2.41 to $3.33
• 52-Week Range: $1.90 to $6.08
• Volume: 404,434 shs
• Average Volume: 1.04 million shs
• Market Capitalization: $224.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Codexis Stock Analysis - MarketRank™

Codexis scored higher than 70% of companies evaluated by MarketBeat, and ranked 329th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Codexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Codexis has a consensus price target of $11.00, representing about 341.8% upside from its current price of $2.49.

Amount of Analyst Coverage

Codexis has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Codexis are expected to grow in the coming year, from ($0.77) to ($0.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Codexis is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Codexis is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Codexis has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.65% of the float of Codexis has been sold short.

Short Interest Ratio / Days to Cover

Codexis has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Codexis has recently decreased by 3.66%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Codexis does not currently pay a dividend.

Dividend Growth

Codexis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 2.5 / 5
• Environmental Score: -3.67

Percentage of Shares Shorted

5.65% of the float of Codexis has been sold short.

Short Interest Ratio / Days to Cover

Codexis has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Codexis has recently decreased by 3.66%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.19

News Sentiment

Codexis has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Codexis this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Codexis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.90% of the stock of Codexis is held by insiders.

Percentage Held by Institutions

78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CDXS Stock Analysis - Frequently Asked Questions

How have CDXS shares performed this year?

Codexis' stock was trading at $4.77 at the beginning of the year. Since then, CDXS shares have decreased by 47.8% and is now trading at $2.49.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Wednesday, August, 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company had revenue of $15.33 million for the quarter, compared to analyst estimates of $14.18 million. Codexis had a negative trailing twelve-month return on equity of 105.83% and a negative net margin of 113.67%.
Read the conference call transcript.

Who are Codexis' major shareholders?

Codexis' top institutional shareholders include Opaleye Management Inc. (15.21%), Aberdeen Group plc (5.07%), Nantahala Capital Management LLC (4.87%) and Telemark Asset Management LLC (4.83%). Insiders that own company stock include Opaleye Management Inc, John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett and Margaret Nell Fitzgerald.
View institutional ownership trends.

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CDXS
• CIK: 1200375
• Web: www.codexis.com
• Phone: (650) 421-8100
• Fax: 650-421-8102
• Employees: 250
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Codexis: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +341.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.28 million
• Net Margins: -113.67%
• Pretax Margin: -113.61%
• Return on Equity: -105.83%
• Return on Assets: -46.06%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 5.82
• Quick Ratio: 5.70

Sales & Book Value

• Annual Sales: $57.16 million
• Price / Sales: 3.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.82 per share
• Price / Book: 3.04

Miscellaneous

• Outstanding Shares: 90,267,000
• Free Float: 88,552,000
• Market Cap: $224.76 million
• Optionable: Optionable
• Beta: 2.54